ReviewMolecular neurobiology2002
Tau function and dysfunction in neurons: its role in neurodegenerative disorders.
Review in Molecular neurobiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 60 citations in OpenAlex.
- Studying Microtubule Dynamics in Human Neurons: Two-Dimensional Microtubule Tracing and Kymographs in iPSC- and SH-SY5Y-Derived Neurons for Tau Research.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review).Molecular medicine reports · 2018Review
- S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model.PloS one · 2014Article
- Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.Frontiers in aging neuroscience · 2014Article
- RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site.Molecular and cellular biology · 2011Article
- Amyloid-beta peptide binds to microtubule-associated protein 1B (MAP1B).Neurochemistry international · 2008Article
- Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.The American journal of pathology · 2007Article
- Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice.Neurotoxicity research · 2004Article
- Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.Neuromolecular medicine · 2003Review
- Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview.Journal of communication disordersReview
- Intracellular A-beta amyloid, a sign for worse things to come?Molecular neurobiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most usual neurodegenerative disorder leading to dementia in the aged human population. It is characterized by the presence of two main brain pathological hallmarks: senile plaques and neurofibrillary tangles (NFTs). NFTs are composed of fibrillar polymers of the abnormally phosphorylated cytoskeletal protein tau.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.